Coverage · Live since 1 July 2026
Medicare now covers weight-loss drugs, with a $50 copay
For the first time, Medicare covers weight-loss medication. The Medicare GLP-1 Bridge runs from 1 July 2026 through 31 December 2027, costs Medicare about $245 a month per patient, and caps the beneficiary copay at $50. If you are eligible, this is almost certainly cheaper than anything in our price database.
What it covers
Injectable weight-loss medications including Ozempic, Wegovy, Mounjaro and Zepbound, for eligible people with severe obesity or a related condition. The programme is structured as a time-limited bridge — a pilot with a defined end date, not a permanent benefit — ahead of broader Part D arrangements.
Why it changes the calculation completely
A $50 monthly copay is below the cheapest compounded program in our entire dataset. The floor here is $169 a month all-in for tirzepatide and $129 for semaglutide, and neither competes with $50 for an FDA-approved product.
So the honest advice to any Medicare-eligible reader is: establish your eligibility for the Bridge before reading another page of this site. Every cash price we publish is aimed at people without a coverage route, and if you have one, our rankings are the wrong tool.
The parts worth reading carefully
It is time-limited. The programme runs to the end of 2027, and what happens after is a policy question nobody can answer today. Anyone building a multi-year treatment plan around it should know that.
It is eligibility-gated. Severe obesity or a qualifying related condition, not weight loss on request. The documentation requirements are the usual ones, and our insurance and appeals guide covers the prior-authorisation sequence that applies.
What it means for compounded programs
It removes the Medicare-eligible population from the compounded market almost entirely, which is a meaningful share of the people with the highest clinical need. Combined with roughly $350 brand pricing through the federal platform, the compounded lane is being squeezed from both ends at once — by an approved product that got cheaper and by a coverage route that made it free-ish for the people who most need it.
Verified . Regulatory positions, prices and trial results move — check the primary source before relying on a date. Compounded tirzepatide and semaglutide are not FDA-approved products.
Questions
Does Medicare cover weight-loss drugs in 2026?
Yes. The Medicare GLP-1 Bridge runs from 1 July 2026 through 31 December 2027 and covers injectable weight-loss medications including Ozempic, Wegovy, Mounjaro and Zepbound for eligible people with severe obesity or a related condition.
What is the copay for Medicare GLP-1 coverage?
A maximum of $50 a month for the beneficiary. Medicare pays about $245 a month per patient.
Is Medicare coverage cheaper than compounded GLP-1s?
Substantially. A $50 copay is below the cheapest compounded program in this database, where the floor is $169 a month all-in for tirzepatide. If you are eligible, coverage beats every cash price we publish.
How long does the Medicare GLP-1 Bridge last?
It is a time-limited pilot running from 1 July 2026 to 31 December 2027. What replaces it is an open policy question.